Volume 132, Issue 5, Pages 1672-1683 (May 2007) Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial  Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak, Bret A. Lashner, Remo Panaccione, Daniel H. Present, Martina E. Spehlmann, Paul J. Rutgeerts, Zsolt Tulassay, Miroslava Volfova, Douglas C. Wolf, Chito Hernandez, Jeffrey Bornstein, William J. Sandborn  Gastroenterology  Volume 132, Issue 5, Pages 1672-1683 (May 2007) DOI: 10.1053/j.gastro.2007.03.024 Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

Figure 1 Study flow diagram. Gastroenterology 2007 132, 1672-1683DOI: (10.1053/j.gastro.2007.03.024) Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

Figure 2 Enrollment, treatment, and outcome of patients in the ENCORE trial. Gastroenterology 2007 132, 1672-1683DOI: (10.1053/j.gastro.2007.03.024) Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

Figure 3 The primary end point was induction of response (≥70-point decrease from baseline CDAI score) at Week 8 that was sustained through Week 12. (A) Proportion of patients with a clinical response (≥70-point decrease from baseline CDAI score). The secondary end points were induction of remission (CDAI score <150) at Week 8 that were sustained through Week 12 and the proportion of patients in response or remission at Week 12. (B) Proportion of patients in clinical remission (CDAI score <150). (C) Proportion of patients with ≥100-point decrease from baseline CDAI score. Significant differences between the treatment groups are noted. Gastroenterology 2007 132, 1672-1683DOI: (10.1053/j.gastro.2007.03.024) Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions

Figure 4 (A) Mean serum CRP concentration (mg/L) at each visit. (B) Mean platelet count (×10 9/L) at each visit. (C) Mean serum albumin concentration (g/L) at each visit. P values reflect a statistically significant difference between treatment groups. Gastroenterology 2007 132, 1672-1683DOI: (10.1053/j.gastro.2007.03.024) Copyright © 2007 American Gastroenterological Association Institute Terms and Conditions